2024
Anesthetic Risk with Large Mediastinal Masses: A Management Framework Based on a Systematic Review
Saffarzadeh A, Popescu W, Detterbeck F, Li A, Blasberg J. Anesthetic Risk with Large Mediastinal Masses: A Management Framework Based on a Systematic Review. The Annals Of Thoracic Surgery 2024 PMID: 39307215, DOI: 10.1016/j.athoracsur.2024.09.011.Peer-Reviewed Original ResearchMediastinal massSystematic reviewManagement of patientsVery-high-riskDegree of airwayDegree of symptomsAnatomic compressionRespiratory decompensationRetrospective seriesVascular compressionCase reportAnesthetic managementCategories of low-Anesthetic riskWriting panelIndividual patientsLow riskPubMed databaseDecompensationPatientsHigher-riskPotential decompensationAnesthesiaBack-up planReactive interventionsThe Scenic Route: Lingular Metastasectomy Through the Right Chest
Udelsman B, Blasberg J. The Scenic Route: Lingular Metastasectomy Through the Right Chest. Annals Of Thoracic Surgery Short Reports 2024, 2: 506-508. DOI: 10.1016/j.atssr.2024.03.010.Peer-Reviewed Original ResearchRight chestMinimally invasive wedge resectionIsolated pulmonary metastasesIpsilateral chestIsolated metastasisOverall-survivalPulmonary metastasesSurgical resectionWedge resectionAnterior mediastinumThoracoscopic approachDisease-freeLeft thoracotomyResectionMetastasectomyChestMetastasisPatientsPleurodesisMediastinumThoracotomyLongitudinal Follow-up of Medicare Patients after Esophageal Cancer Resection in the STS Database
Blasberg J, Servais E, Thibault D, Jacobs J, Kozower B, David E, Donahue J, Vekstein A, Kang L, Hartwig M, Jones L, Kosinski A, Habib R, Towe C, Seder C. Longitudinal Follow-up of Medicare Patients after Esophageal Cancer Resection in the STS Database. The Annals Of Thoracic Surgery 2024 PMID: 39147116, DOI: 10.1016/j.athoracsur.2024.07.034.Peer-Reviewed Original ResearchIncreased mortality riskLong-term mortalityMedicare patientsMortality riskDays post-surgeryPost-surgeryCox proportional hazards modelsMultivariate Cox proportional hazards modelDown-staged patientsCharacteristics associated with survivalEsophageal cancer resectionPreoperative risk stratificationProportional hazards modelLog-rank testLong-term survivalDeterministic matching algorithmLongitudinal follow-upPatient-specific predictorsShort-term mortalityCumulative incidence curvesDownstaged patientsN downstagingSTS databasePathological TCancer resectionAssessment of online information on robotic cardiac and thoracic surgery
Hameed I, Amabile A, Candelario K, Khan S, Li E, Fereydooni S, Almeida M, Latif N, Ahmed A, Dhanasopon A, Krane M, Blasberg J, Geirsson A. Assessment of online information on robotic cardiac and thoracic surgery. Journal Of Robotic Surgery 2024, 18: 41. PMID: 38231324, DOI: 10.1007/s11701-023-01794-6.Peer-Reviewed Original ResearchConceptsThoracic surgeryAmount of contentConfidence intervalsOnline informationReadability of online resourcesOnline health informationSystematic online searchPerioperative informationCardiothoracic surgeonsOnline health resourcesAcademic websitesSurgeryPatientsReadability of websitesThoracicMultivariate regressionHigher accuracyWebsite accuracyPatient useHealth informationReadabilityWebsitesAccuracyAssociated with higher accuracyIndependent panel
2023
So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer
Detterbeck F, Ely S, Udelsman B, Blasberg J, Boffa D, Dhanasopon A, Mase V, Woodard G. So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer. Clinical Lung Cancer 2023, 25: e113-e123. PMID: 38310034, DOI: 10.1016/j.cllc.2023.12.007.Peer-Reviewed Original ResearchStage I lung cancerI lung cancerSublobar resectionRecurrence-free survivalHealthy patientsLung cancerRecent trialsInadequate resection marginsLarge recent trialsAdditional randomized trialsHigh-level evidenceOverall survival differenceExtent of resectionLong-term outcomesLong-term resultsHigh locoregional recurrenceAspects of patientsLesser resectionsLocoregional recurrencePerioperative morbidityIntraoperative detailsLung functionResection extentResection marginsPostoperative changes
2022
Thoracic CT follow-up after non-small-cell lung cancer resection
Woodard G, Boffa D, Blasberg J. Thoracic CT follow-up after non-small-cell lung cancer resection. The Lancet Oncology 2022, 23: e484. PMID: 36328013, DOI: 10.1016/s1470-2045(22)00618-0.Commentaries, Editorials and LettersThe Society of Thoracic Surgeons General Thoracic Surgery Database: 2022 Update on Outcomes and Research
Servais E, Blasberg J, Brown L, Towe C, Seder C, Onaitis M, Block M, David E. The Society of Thoracic Surgeons General Thoracic Surgery Database: 2022 Update on Outcomes and Research. The Annals Of Thoracic Surgery 2022, 115: 43-49. PMID: 36404445, DOI: 10.1016/j.athoracsur.2022.10.025.Peer-Reviewed Original ResearchImmunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy useSurgical Management of Pneumothorax and Pleural Space Disease
Dhanasopon AP, Blasberg JD, Mase VJ. Surgical Management of Pneumothorax and Pleural Space Disease. Surgical Clinics Of North America 2022, 102: 413-427. PMID: 35671764, DOI: 10.1016/j.suc.2022.03.001.Peer-Reviewed Original ResearchA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making
Detterbeck FC, Blasberg JD, Woodard GA, Decker RH, Kumbasar U, Park HS, Mase VJ, Bade BC, Li AX, Brandt WS, Madoff DC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813719, PMCID: PMC9264102, DOI: 10.21037/jtd-21-1823.Peer-Reviewed Original ResearchLong-term outcomesIndividual patientsHealthy patientsLung cancerFavorable tumorsStage I lung cancerBetter long-term outcomesI lung cancerStage I NSCLCOlder patientsPatient selectionPoint of careSurgical approachClinical careEffect modifiersTreatment selectionPatientsTreatment approachesPatient valuesClinical judgmentSystematic reviewRelevant outcomesLong-term differencesAvailable evidenceShort-term differencesA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients
Detterbeck FC, Mase VJ, Li AX, Kumbasar U, Bade BC, Park HS, Decker RH, Madoff DC, Woodard GA, Brandt WS, Blasberg JD. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813747, PMCID: PMC9264068, DOI: 10.21037/jtd-21-1824.Peer-Reviewed Original ResearchNon-randomized comparisonHealthy patientsResection extentIndividual patientsSystematic reviewStage I lung cancerI lung cancerStage I NSCLCCharacteristics of patientsPulmonary function testsLong-term outcomesRisk of recurrenceVideo-assisted approachSublobar resectionWedge resectionRandomized trialsFunction testsLung cancerResidual confoundingEffect modifiersShort-term benefitsLobectomyPatientsPubMed systematic reviewMargin distanceA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors
Bade BC, Blasberg JD, Mase VJ, Kumbasar U, Li AX, Park HS, Decker RH, Madoff DC, Brandt WS, Woodard GA, Detterbeck FC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813753, PMCID: PMC9264070, DOI: 10.21037/jtd-21-1825.Peer-Reviewed Original ResearchLimited pulmonary reserveLong-term outcomesResection extentNon-randomized comparisonPulmonary reserveOlder patientsIndividual patientsFavorable tumorsSystematic reviewStage I lung cancerFavorable long-term outcomeI lung cancerScreen-detected tumorsStage I NSCLCCharacteristics of patientsShort-term outcomesLesser resectionsPerioperative mortalityPulmonary functionSublobar resectionWedge resectionPatient selectionRandomized trialsLung cancerResidual confoundingA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation
Park HS, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813762, PMCID: PMC9264060, DOI: 10.21037/jtd-21-1826.Peer-Reviewed Original ResearchLong-term outcomesNon-randomized comparisonIndividual patientsSystematic reviewStage I lung cancerI lung cancerCharacteristics of patientsStage I NSCLCPulmonary function testsMinority of patientsShort-term outcomesStereotactic body radiotherapyThermal ablationLate toxicityPulmonary functionRandomized trialsFunction testsAdjusted comparisonsBody radiotherapyLung cancerResidual confoundingEffect modifiersShort-term benefitsPatientsPubMed systematic reviewMicrowave Ablation versus Stereotactic Body Radiotherapy for Stage I Non–Small Cell Lung Cancer: A Cost-Effectiveness Analysis
Wu X, Uhlig J, Blasberg JD, Gettinger SN, Suh RD, Solomon SB, Kim HS. Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non–Small Cell Lung Cancer: A Cost-Effectiveness Analysis. Journal Of Vascular And Interventional Radiology 2022, 33: 964-971.e2. PMID: 35490932, DOI: 10.1016/j.jvir.2022.04.019.Peer-Reviewed Original ResearchRevisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasis109MO Respect the middle lobe: Perioperative survival of bilobectomy compared to lobectomy and pneumonectomy
Li A, Canavan M, Ermer T, Kaminski M, Maduka R, Zhan P, Flores K, Boffa D, Blasberg J. 109MO Respect the middle lobe: Perioperative survival of bilobectomy compared to lobectomy and pneumonectomy. Annals Of Oncology 2022, 33: s82. DOI: 10.1016/j.annonc.2022.02.136.Peer-Reviewed Original Research
2021
Breast metastases from primary lung cancer: a retrospective case series on clinical, ultrasonographic, and immunohistochemical features
Wang B, Jiang Y, Li SY, Niu RL, Blasberg JD, Kaifi JT, Liu G, Wang ZL. Breast metastases from primary lung cancer: a retrospective case series on clinical, ultrasonographic, and immunohistochemical features. Translational Lung Cancer Research 2021, 0: 0-0. PMID: 34430360, PMCID: PMC8350075, DOI: 10.21037/tlcr-21-542.Peer-Reviewed Original ResearchPrimary lung cancerRetrospective case seriesBreast metastasisLung cancerCase seriesImmunohistochemical featuresCytokeratin 7Breast nodulesPrimary breast malignancyThyroid transcription factor-1Lung cancer metastasisAxillary lymphadenopathyClinical featuresLung metastasesImmunohistochemical findingsTranscription factor 1Ultrasonographic featuresBreast malignancyUltrasound featuresUltrasonographic characteristicsImmunohistochemical dataClinical practiceMetastasisNapsin A.CancerOutcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis
Li AX, Resio BJ, Canavan ME, Papageorge M, Boffa DJ, Blasberg JD. Outcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis. Journal Of Thoracic Disease 2021, 0: 0-0. PMID: 34277037, PMCID: PMC8264694, DOI: 10.21037/jtd-21-1.Peer-Reviewed Original ResearchPrimary lung sarcomaNational Cancer DatabaseLung sarcomaOverall survivalSurgical resectionMultivariable Cox proportional hazards modelsNon-small cell lung cancer patientsNational Cancer Database AnalysisCell lung cancer patientsCox proportional hazards modelCharlson-Deyo scoreFive-year OSMultivariable Cox modelPositive lymph nodesMajority of patientsLung cancer patientsHigh tumor gradeHigh-grade tumorsDifferent histologic subtypesProportional hazards modelAdjuvant chemotherapyParenchymal resectionPulmonary malignancyWorse survivalAdjusted mortalityEvolution of the N Descriptor Lymph Node Number vs Lymph Node Location
Blasberg JD, Li A. Evolution of the N Descriptor Lymph Node Number vs Lymph Node Location. CHEST Journal 2021, 159: 2159-2160. PMID: 34099129, DOI: 10.1016/j.chest.2021.01.065.Peer-Reviewed Original ResearchHigh expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases
Dai L, Li YH, Liang YY, Zhao J, Chen G, Yin J, Postmus PE, Addeo A, Blasberg JD, Onesti CE, Liao ZW, Rao XG, Long HD. High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases. Journal Of Thoracic Disease 2021, 13: 2437-2446. PMID: 34012591, PMCID: PMC8107517, DOI: 10.21037/jtd-21-307.Peer-Reviewed Original ResearchNon-small cell lung cancer patientsCell lung cancer patientsBrain metastasesKaplan-Meier analysisNSCLC patientsLung cancer patientsCell adhesion molecule 2Overall survivalCox analysisPoor prognosisCancer patientsAffiliated Cancer HospitalHigh expressionIndependent risk factorSolid organ malignanciesOS of patientsCADM2 expressionLymph node metastasisTumor T stagePotential prognostic significanceGuangzhou Medical UniversityExpression levelsReal-time polymerase chain reactionQuantitative real-time polymerase chain reactionChi-square test